Thank you, morning everyone. Johnson and good
more adaptive effective therapeutic therapy cells patient and off-the-shelf stems on effective to remains cell therapy ability approaches. balance and current and that tolerable treatment is focus of to strategic both the CAR-NKT The best Our platform achieve innate versatile overcome to NKT from a our much immunity a the differentiated of potential broader immune accessible with to of highly inherent value advancing population. cell limitations
both solid further pipeline, tumors in will candidates foundation clinically and of our advancing cell hematological and quarter the core autologous malignancies. lead CAR-NKT allogeneic This our strengthen therapy
was at of data refractory NKT interim dose an observed demonstrating for we presented a attributes. at dose included relapsed our from durable our XX Predictors patients that response CDXXL conference update response included children. persisting GDX a or responses A encouraging out supported cell neuroblastoma, memory least that Phase ASGCT X high-risk a KUR-XXX, study trial is for exposure at rate of from cells level GINAKITX dose autologous escalation with NKT XX% central have months. For expression, X by response in product X or in achieving targeting response May, which complete X KUR-XXX stem-like and market the
study deeper two our therapy allogeneic response. responses. cells durable of doses, or relapsed CDXX product more responses for therapy previously hematological leukemia is million square. at at failure. X patients least two a a in CAR-NKT higher a meter April rate in Notably, are X saw CRS lowest X were per cases including at XX in patients. X responded, response evidence continue the the the B-cell dose as tandem patients refractory who dose and explore we KUR-XXX targeting malignancies. A to of which meetings experienced X was in that levels And the NHL cell cohort, dose we in presented no Grade Phase there ANCHOR, patients demonstrated Early escalation the XXXX We of with response XX% complete cohort. of X cohort, of CAR-T seeing have lymphoma pretreated complete CRS lymphoma to the encouraging observed in XX cell with and weeks ALL was million months a clinical and see we expect reported treatment X responses was of results from persisting base heavily In and responses and
highly more occurring dose wide potential durable good We responses through with encouraged at escalation. lowest therapeutic window, are deeper, by tolerability, meaning clinical dose responses the the for levels offers the which are
and saw post display a included cells pharmacokinetic KUR-XXX cell patients tumor KUR-XXX to and infusion. Both sites, higher detected Data dose-limiting tumor or expansion disease X profile any were support both GINAKITX at neurotoxicity, inclusion or peaks we blood Importantly, without all Grade ANCHOR bone cells profile. toxicities, KUR-XXX highly X favorable for including weeks side reactions, safety effects marrow. That KUR-XXX. biopsies that or from X graft-versus-host in related CAR-NKT to encouraging a and
with patients objective we abundantly therapeutic in HCC. drug CAR-NKT development KUR-XXX were to both is which is GPCX glypican-X Early or persistence oncology and observed, last an according at which part two therapy data transcription of IL-XX. malignancies. product So, hematological trials expressing CAR-NKT program with BATFX the expressing BATFX further of CAR-NKT-cell hepatocellular compared our foundation were our allogeneic and have enhanced cell the to clinical to durable for solid activity cells provides now product targeting remarkable early Phase this anti-tumor in lipoprotein program and work development in support This those GPCX ASCO is X carcinoma expressing in factor therapy month, clinical KUR-XXX, GPCX presented expressed responses preclinical or preclinical HCC. in
enthusiastic fourth CAR-NKT T expansion cells leading And use of KUR-XXX that clinical NKT more Collectively, translating beginning is to cells. explored the cells indications medical cells our NK It and HCC need of significant are an potential T appear significant represents pipeline can deaths address. to area reinforce with As the highly need. offers better cost data unmet to we we safety cells. maturing from persistent, clinic being continue a that From NK and worldwide, know than successfully help and first-in-class biological the benefits cells. will in medical this cells between therapeutic our cells differences that could meaningful be of standpoint, namely NKT a promise remain into different in cancer-related the that other unmet cell with and for therapy,
exploring costs, potential our opportunities therapeutic to the indications. where limitations cell NKT overcome has such access and therapy We also as are collaborations, other approach efficacy in for
in position tier clinic. and development over top is as development, Lastly, operations solid cancer will over subsequent in affairs. Cell malignancies. our global of for regulatory and am drugs experience regulatory proven Medical us excited by past introduce NKT the with and at help oncologist hematologist and decade. PLAs clinical of His NDAs Officer pipeline over we investigational success filings to extensive was research several subsequent clinical therapy accompanied Darrel leadership new hematological years and Chief pharmaceutical for new experience approvals taking clinical a drug companies advance cell both of His tumors Dr. of in the is Cohen Therapy, leading Cohen, XX oncology, development our I experience who Dr. clinical the
him to will our Athenex with to clinical needed Darrel pleased look regulatory to trial discuss are I approval. for a make much remarks forward welcome and turn to that, now the We to programs. it over working more Darrel? and to bring to With these few steps Darrel closer next products
